Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

COVID-19

Free Subscription Articles published in Lancet Infect Dis Retrieve available abstracts of 409 articles: HTML format

Single Articles

May 2026
1. HANSEN CH, Soborg B, Rasmussen M, Moustsen-Helms IR, et al
   Effectiveness of the BNT162b2 LP.8.1-adapted SARS-CoV-2 vaccine against COVID-19-associated hospitalisation and death: a Danish nationwide cohort study.
   Lancet Infect Dis. 2026 May 13:S1473-3099(26)00236.
   PubMed    
   
   
   April 2026
2. RITCHIE AJ, Hassan O, Urasa N, Apanga PA, et al
   Safety and immunogenicity of a single-dose adenovirus-vectored rabies vaccine over 1 year in adults and children in Tanzania: interim data from an ongoing, partly randomised, controlled, phase 1b/2 trial.
   Lancet Infect Dis. 2026 Apr 28:S1473-3099(26)00071.
   PubMed     Abstract available
   
   
   
3. ZHANG L, Hoffmann M, Pohlmann S
   Does BA.3.2 epidemiology imply a change in SARS-CoV-2 evolution?
   Lancet Infect Dis. 2026 Apr 17:S1473-3099(26)00192.
   PubMed    
   
   
   March 2026
4. CAMICI M, Piano Mortari E, Del Duca G, Cimini E, et al
   Intravenous immunoglobulin treatment for long COVID: a case report of clinical and immunological findings.
   Lancet Infect Dis. 2026 Mar 31:S1473-3099(26)00063.
   PubMed     Abstract available
   
   
   
5. WALKER MK, Yek C, Sarzynski S, Warner S, et al
   Survival trends in patients with difficult-to-treat, antibiotic-resistant, Gram-negative infections in the era of next-generation antibiotics in the USA: a retrospective cohort study.
   Lancet Infect Dis. 2026 Mar 25:S1473-3099(26)00020.
   PubMed     Abstract available
   
   
   
6. BIJUKCHHE SM, Marchevsky NG, Kibengo F, Sharma AK, et al
   Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.
   Lancet Infect Dis. 2026 Mar 19:S1473-3099(26)00053.
   PubMed     Abstract available
   
   
   February 2026
7. KUPPALLI K
   I worked at WHO: the USA leaving will not make America healthier.
   Lancet Infect Dis. 2026 Feb 13:S1473-3099(26)00069.
   PubMed    
   
   
   
8. LASRADO N, Rossler A, Molloy K, McConnell I, et al
   Overcoming immune imprinting with the COVID-19 LP.8.1 mRNA boosters.
   Lancet Infect Dis. 2026 Feb 9:S1473-3099(26)00050.
   PubMed    
   
   
   January 2026
9. KAKU Y, Fujiwara M, Uriu K, Yo MS, et al
   Humoral immunity after LP.8.1 monovalent vaccines against a broad range of SARS-CoV-2 variants including XEC, LP.8.1, NB.1.8.1, XFG, and BA.3.2.
   Lancet Infect Dis. 2026 Jan 12:S1473-3099(25)00772.
   PubMed    
   
   
   
10. LEITNER DR, Walsh SR, Suzuki M, Desjardins M, et al
    Safety and immunogenicity of PanChol, a single-dose live-attenuated oral cholera vaccine: results from a phase 1a, double-blind, randomised, placebo-controlled trial.
    Lancet Infect Dis. 2026 Jan 7:S1473-3099(25)00682.
    PubMed     Abstract available
    
    
    December 2025
11. 
    Global burden of lower respiratory infections and aetiologies, 1990-2023: a systematic analysis for the Global Burden of Disease Study 2023.
    Lancet Infect Dis. 2025 Dec 15:S1473-3099(25)00689.
    PubMed     Abstract available
    
    
    November 2025
12. HAPPLE C, Hoffmann M, Stankov MV, Nehlmeier I, et al
    Effects of LP.8.1-adapted mRNA vaccination on SARS-CoV-2 variant neutralisation.
    Lancet Infect Dis. 2025 Nov 21:S1473-3099(25)00690.
    PubMed    
    
    
    
13. CHOSIDOW A, Maakaroun-Vermesse Z, Ok V, Delecroix C, et al
    Post-COVID-19 resurgence of Mycoplasma pneumoniae infections in French children (ORIGAMI): a retrospective and prospective multicentre cohort study.
    Lancet Infect Dis. 2025 Nov 19:S1473-3099(25)00598.
    PubMed     Abstract available
    
    
    
14. MENTZER AJ, Smith GD, Lambe T, Knight JC, et al
    Time to tackle vaccine-HLA associations with artificial intelligence.
    Lancet Infect Dis. 2025 Nov 17:S1473-3099(25)00687.
    PubMed    
    
    
    
15. ZHANG L, Chen N, Eichmann A, Nehlmeier I, et al
    Epidemiological and virological update on the emerging SARS-CoV-2 variant BA.3.2.
    Lancet Infect Dis. 2025 Nov 12:S1473-3099(25)00658.
    PubMed    
    
    
    
16. ANYWAINE Z, Serwanga J, Ggayi AM, Abaasa AM, et al
    Safety, tolerability, and immunogenicity of the ChAdOx1 RVF vaccine against Rift Valley fever among healthy adults in Uganda: a single-centre, single-blind, randomised, placebo-controlled, dose-escalation, phase 1 trial.
    Lancet Infect Dis. 2025 Nov 11:S1473-3099(25)00565.
    PubMed     Abstract available
    
    
    October 2025
17. BAGER P, Svalgaard IB, Christiansen LE, Lomholt FK, et al
    COVID-19 versus influenza burden in Denmark in the 2024-25 season.
    Lancet Infect Dis. 2025 Oct 27:S1473-3099(25)00604.
    PubMed    
    
    
    
18. SYMES R, Whitaker HJ, Ahmad S, Arnold D, et al
    Vaccine effectiveness of a bivalent respiratory syncytial virus (RSV) pre-F vaccine against RSV-associated hospital admission among adults aged 75-79 years in England: a multicentre, test-negative, case-control study.
    Lancet Infect Dis. 2025 Oct 27:S1473-3099(25)00546.
    PubMed     Abstract available
    
    
    
19. SCHILLING WHK, Jittamala P, Wongnak P, Watson JA, et al
    Antiviral efficacy of oral ensitrelvir versus oral ritonavir-boosted nirmatrelvir in COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00482.
    PubMed     Abstract available
    
    
    
20. HONG CM, Hung IFN
    Beyond ritonavir-boosted nirmatrelvir: the case for ensitrelvir in COVID-19 treatment.
    Lancet Infect Dis. 2025 Oct 10:S1473-3099(25)00549.
    PubMed    
    
    
    September 2025
21. ZHANG B, Wu Q, Jhaveri R, Zhou T, et al
    Long COVID associated with SARS-CoV-2 reinfection among children and adolescents in the omicron era (RECOVER-EHR): a retrospective cohort study.
    Lancet Infect Dis. 2025 Sep 30:S1473-3099(25)00476.
    PubMed     Abstract available
    
    
    
22. WILHELM F, Cadamuro J, Mink S
    Autoantibodies in long COVID: a systematic review.
    Lancet Infect Dis. 2025 Sep 8:S1473-3099(25)00411.
    PubMed     Abstract available
    
    
    
23. JOHNSON A
    Racism in the COVID-19 pandemic.
    Lancet Infect Dis. 2025;25:964.
    PubMed    
    
    
    August 2025
24. 
    Sotrovimab versus usual care in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    Lancet Infect Dis. 2025 Aug 28:S1473-3099(25)00361.
    PubMed     Abstract available
    
    
    
25. FOCOSI D, Maggi F
    Reassessing sotrovimab's role in COVID-19: insights and implications.
    Lancet Infect Dis. 2025 Aug 28:S1473-3099(25)00410.
    PubMed    
    
    
    
26. VON LILIENFELD-TOAL M, Khawaja F, Compagno F, Robin C, et al
    Community-acquired respiratory virus infections in patients with haematological malignancies or undergoing haematopoietic cell transplantation: updated recommendations from the 10th European Conference on Infections in Leukaemia.
    Lancet Infect Dis. 2025 Aug 27:S1473-3099(25)00365.
    PubMed     Abstract available
    
    
    
27. LIU C, Rosen EA, Stohs EJ, Imlay H, et al
    Tackling antimicrobial resistance in people who are immunocompromised: leveraging diagnostic and antimicrobial stewardship.
    Lancet Infect Dis. 2025 Aug 11:S1473-3099(25)00311.
    PubMed     Abstract available
    
    
    
28. RANSCOMBE P
    The quirky story behind New York's SARS-CoV-2 preparations.
    Lancet Infect Dis. 2025 Aug 8:S1473-3099(25)00505.
    PubMed    
    
    
    
29. NGUYEN-TRAN H, Park SW, Vogt MR, Permaul P, et al
    Dynamics of endemic virus re-emergence in children in the USA following the COVID-19 pandemic (2022-23): a prospective, multicentre, longitudinal, immunoepidemiological surveillance study.
    Lancet Infect Dis. 2025 Aug 6:S1473-3099(25)00349.
    PubMed     Abstract available
    
    
    July 2025
30. HANSEN CH, Lassauniere R, Rasmussen M, Moustsen-Helms IR, et al
    Effectiveness of the BNT162b2 and mRNA-1273 JN.1-adapted vaccines against COVID-19-associated hospitalisation and death: a Danish, nationwide, register-based, cohort study.
    Lancet Infect Dis. 2025 Jul 29:S1473-3099(25)00380.
    PubMed     Abstract available
    
    
    
31. BROSH-NISSIMOV T
    Refining COVID-19 care for immunocompromised patients.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00316.
    PubMed    
    
    
    
32. WEINSTEIN E, Paredes R, Gardner A, Almas M, et al
    Extended nirmatrelvir-ritonavir treatment durations for immunocompromised patients with COVID-19 (EPIC-IC): a placebo-controlled, randomised, double-blind, phase 2 trial.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00221.
    PubMed     Abstract available
    
    
    
33. OGBUAGU O, Goldman JD, Gottlieb RL, Singh U, et al
    Efficacy and safety of obeldesivir in low-risk, non-hospitalised patients with COVID-19 (OAKTREE): a phase 3, randomised, double-blind, placebo-controlled study.
    Lancet Infect Dis. 2025 Jul 14:S1473-3099(25)00238.
    PubMed     Abstract available
    
    
    
34. FLAMANT A, Demirjian A, Lamagni T, Toubiana J, et al
    Invasive group A streptococcal infections: lessons learned from the 2022-23 upsurge.
    Lancet Infect Dis. 2025 Jul 9:S1473-3099(25)00343.
    PubMed     Abstract available
    
    
    
35. CHALKIAS S, Dennis P, Petersen D, Radhakrishnan K, et al
    Efficacy, immunogenicity, and safety of a next-generation mRNA-1283 COVID-19 vaccine compared with the mRNA-1273 vaccine (NextCOVE): results from a phase 3, randomised, observer-blind, active-controlled trial.
    Lancet Infect Dis. 2025 Jul 7:S1473-3099(25)00236.
    PubMed     Abstract available
    
    
    June 2025
36. LIU JW, Lai CC, Hsueh PR
    Resurgence of human metapneumovirus in the post-COVID-19 era: pathogenesis, epidemiological shifts, clinical impact, and future challenges.
    Lancet Infect Dis. 2025 Jun 20:S1473-3099(25)00240.
    PubMed     Abstract available
    
    
    
37. URIU K, Okumura K, Uwamino Y, Chen L, et al
    Virological characteristics of the SARS-CoV-2 NB.1.8.1 variant.
    Lancet Infect Dis. 2025 Jun 6:S1473-3099(25)00356.
    PubMed    
    
    
    
38. GUO C, Yu Y, Liu J, Jian F, et al
    Antigenic and virological characteristics of SARS-CoV-2 variants BA.3.2, XFG, and NB.1.8.1.
    Lancet Infect Dis. 2025 Jun 5:S1473-3099(25)00308.
    PubMed    
    
    
    May 2025
39. VENTO S
    COVID-19 mortality in Africa and Asia.
    Lancet Infect Dis. 2025 May 29:S1473-3099(25)00348.
    PubMed    
    
    
    
40. BEJON P, Agweyu A, Oyier I, Hamaluba M, et al
    COVID-19 mortality in Africa and Asia - Authors' reply.
    Lancet Infect Dis. 2025 May 29:S1473-3099(25)00350.
    PubMed    
    
    
    
41. FOLEGATTI PM, Pepin S, Tabar C, Fries K, et al
    Comparative assessment of immunogenicity and safety of recombinant influenza vaccine in children, adolescents, and adults: results from a phase 3, immunobridging, open-label, non-randomised study.
    Lancet Infect Dis. 2025 May 21:S1473-3099(25)00153.
    PubMed     Abstract available
    
    
    
42. 
    Molnupiravir or nirmatrelvir-ritonavir plus usual care versus usual care alone in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial.
    Lancet Infect Dis. 2025 May 15:S1473-3099(25)00093.
    PubMed     Abstract available
    
    
    
43. LUI GCY, Hui DSC
    Revisiting oral antivirals for COVID-19 in the hospital setting.
    Lancet Infect Dis. 2025 May 15:S1473-3099(25)00169.
    PubMed    
    
    
    
44. SAADATIAN-ELAHI M, Rabilloud M, Mohlmann TWR, Langlois-Jacques C, et al
    Effectiveness of integrated vector management on the incidence of dengue in urban Malaysia: a cluster-randomised controlled trial.
    Lancet Infect Dis. 2025 May 12:S1473-3099(25)00086.
    PubMed     Abstract available
    
    
    April 2025
45. BEJON P, Agweyu A, Ochola-Oyier LI, Hamaluba M, et al
    Rethinking the evidence on COVID-19 in Africa.
    Lancet Infect Dis. 2025 Apr 4:S1473-3099(25)00071.
    PubMed     Abstract available
    
    
    
46. SAWANO M, Bhattacharjee B, Caraballo C, Khera R, et al
    Nirmatrelvir-ritonavir versus placebo-ritonavir in individuals with long COVID in the USA (PAX LC): a double-blind, randomised, placebo-controlled, phase 2, decentralised trial.
    Lancet Infect Dis. 2025 Apr 3:S1473-3099(25)00073.
    PubMed     Abstract available
    
    
    
47. CAI M, Xu E, Xie Y, Al-Aly Z, et al
    Rates of infection with other pathogens after a positive COVID-19 test versus a negative test in US veterans (November, 2021, to December, 2023): a retrospective cohort study.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(24)00831.
    PubMed     Abstract available
    
    
    
48. CHODICK G
    Long-term infectious sequelae after SARS-CoV-2 infection should be considered in mild cases too.
    Lancet Infect Dis. 2025 Apr 1:S1473-3099(25)00074.
    PubMed    
    
    
    March 2025
49. RAMOS B, Vadlamudi NK, Han C, Sadarangani M, et al
    Future immunisation strategies to prevent Streptococcus pneumoniae infections in children and adults.
    Lancet Infect Dis. 2025 Mar 17:S1473-3099(24)00740.
    PubMed     Abstract available
    
    
    
50. HASLAM E
    Lessons from the COVID-19 pandemic.
    Lancet Infect Dis. 2025 Mar 13:S1473-3099(25)00177.
    PubMed    
    
    
    February 2025
51. ZHANG L, Kempf A, Nehlmeier I, Chen N, et al
    Host cell entry and neutralisation sensitivity of the emerging SARS-CoV-2 variant LP.8.1.
    Lancet Infect Dis. 2025 Feb 26:S1473-3099(25)00113.
    PubMed    
    
    
    
52. FOCOSI D, Casadevall A
    Sipavibart: when a success changes into a failure.
    Lancet Infect Dis. 2025 Feb 24:S1473-3099(24)00812.
    PubMed    
    
    
    
53. HAIDAR G, Thomas S, Loubet P, Baker RI, et al
    Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial.
    Lancet Infect Dis. 2025 Feb 24:S1473-3099(24)00804.
    PubMed     Abstract available
    
    
    
54. KRAMMER F, Barclay WS, Beer M, Brown IH, et al
    Europe needs a sustainably funded influenza research and response network.
    Lancet Infect Dis. 2025 Feb 17:S1473-3099(25)00068.
    PubMed    
    
    
    
55. CHEN L, Kaku Y, Okumura K, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 LP.8.1 variant.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(25)00079.
    PubMed    
    
    
    
56. PROAL AD, Aleman S, Bomsel M, Brodin P, et al
    Targeting the SARS-CoV-2 reservoir in long COVID.
    Lancet Infect Dis. 2025 Feb 10:S1473-3099(24)00769.
    PubMed     Abstract available
    
    
    
57. WANG Q, Mellis IA, Wu M, Bowen A, et al
    KP.2-based monovalent mRNA vaccines robustly boost antibody responses to SARS-CoV-2.
    Lancet Infect Dis. 2025 Feb 4:S1473-3099(25)00058.
    PubMed    
    
    
    January 2025
58. SUTHAR MS, Manning KE, Ellis ML, Jain S, et al
    The KP.2-adapted COVID-19 vaccine improves neutralising activity against the XEC variant.
    Lancet Infect Dis. 2025 Jan 31:S1473-3099(25)00007.
    PubMed    
    
    
    
59. XIE Y
    COVID-19 versus influenza: the need to align policies with COVID-19 realities.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(25)00001.
    PubMed    
    
    
    
60. BAGER P, Svalgaard IB, Lomholt FK, Emborg HD, et al
    The hospital and mortality burden of COVID-19 compared with influenza in Denmark: a national observational cohort study, 2022-24.
    Lancet Infect Dis. 2025 Jan 29:S1473-3099(24)00806.
    PubMed     Abstract available
    
    
    
61. LIU J, Yu Y, Yang S, Jian F, et al
    Virological and antigenic characteristics of SARS-CoV-2 variants LF.7.2.1, NP.1, and LP.8.1.
    Lancet Infect Dis. 2025 Jan 28:S1473-3099(25)00015.
    PubMed    
    
    
    
62. ALVES K, Kotloff K, McClelland RS, Kouassi A, et al
    Immunogenicity and safety of a monovalent omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose in US adults: interim analysis of a single-arm phase 2/3 study.
    Lancet Infect Dis. 2025 Jan 14:S1473-3099(24)00670.
    PubMed     Abstract available
    
    
    
63. YADAV PD, Patil DY
    Interim analysis of SARS-CoV-2 vaccine NVX-CoV2601 as a heterologous booster dose.
    Lancet Infect Dis. 2025 Jan 14:S1473-3099(25)00005.
    PubMed    
    
    
    December 2024
64. ROJEK A, Fieggen J, Apiyo P, Caluwaerts S, et al
    Ebola disease: bridging scientific discoveries and clinical application.
    Lancet Infect Dis. 2024 Dec 12:S1473-3099(24)00673.
    PubMed     Abstract available
    
    
    
65. URIU K, Kaku Y, Uwamino Y, Fujiwara H, et al
    Antiviral humoral immunity induced by JN.1 monovalent mRNA vaccines against SARS-CoV-2 omicron subvariants including JN.1, KP.3.1.1, and XEC.
    Lancet Infect Dis. 2024 Dec 10:S1473-3099(24)00810.
    PubMed    
    
    
    November 2024
66. GOSWAMI J, Cardona JF, Hsu DC, Simorellis AK, et al
    Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.
    Lancet Infect Dis. 2024 Nov 25:S1473-3099(24)00589.
    PubMed     Abstract available
    
    
    
67. LIU J, Yu Y, Jian F, Yang S, et al
    Enhanced immune evasion of SARS-CoV-2 variants KP.3.1.1 and XEC through N-terminal domain mutations.
    Lancet Infect Dis. 2024 Nov 22:S1473-3099(24)00738.
    PubMed    
    
    
    
68. ARORA P, Happle C, Kempf A, Nehlmeier I, et al
    Impact of JN.1 booster vaccination on neutralisation of SARS-CoV-2 variants KP.3.1.1 and XEC.
    Lancet Infect Dis. 2024 Nov 7:S1473-3099(24)00688.
    PubMed    
    
    
    
69. KAKU Y, Okumura K, Kawakubo S, Uriu K, et al
    Virological characteristics of the SARS-CoV-2 XEC variant.
    Lancet Infect Dis. 2024 Nov 6:S1473-3099(24)00731.
    PubMed    
    
    
    October 2024
70. OKADA Y, Kumagai Y, Okura I, Otsuki M, et al
    Immunogenicity of a booster dose of a bivalent (Asp614Gly and omicron BA.4/5 variant) self-amplifying mRNA SARS-CoV-2 booster vaccine versus the BNT162b2 omicron BA.4/5 mRNA vaccine: a randomised phase 3 trial.
    Lancet Infect Dis. 2024 Oct 23:S1473-3099(24)00565.
    PubMed     Abstract available
    
    
    
71. PASCAL G
    COVID-19 in South Asia.
    Lancet Infect Dis. 2024 Oct 22:S1473-3099(24)00723.
    PubMed    
    
    
    
72. WANG Y, So HC, Tsang NNY, Kwok SK, et al
    Clinical profile analysis of SARS-CoV-2 community infections during periods with omicron BA.2, BA.4/5, and XBB dominance in Hong Kong: a prospective cohort study.
    Lancet Infect Dis. 2024 Oct 14:S1473-3099(24)00574.
    PubMed     Abstract available
    
    
    
73. NAKAKUBO S
    Evolving COVID-19 symptoms and the ongoing course of research.
    Lancet Infect Dis. 2024 Oct 14:S1473-3099(24)00668.
    PubMed    
    
    
    
74. RAADSEN MP, Dahlke C, Fathi A, Hardtke S, et al
    Safety, immunogenicity, and optimal dosing of a modified vaccinia Ankara-based vaccine against MERS-CoV in healthy adults: a phase 1b, double-blind, randomised placebo-controlled clinical trial.
    Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00423.
    PubMed     Abstract available
    
    
    
75. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
    12-month persistence of immune responses to self-amplifying mRNA COVID-19 vaccines: ARCT-154 versus BNT162b2 vaccine.
    Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00615.
    PubMed    
    
    
    
76. BATAWI SA, Alraddadi BM
    Revisiting MERS-CoV vaccination in the SARS-CoV-2 era.
    Lancet Infect Dis. 2024 Oct 7:S1473-3099(24)00453.
    PubMed    
    
    
    
77. RAMGOLAM A
    COVID-19 and sexual health rights in Africa.
    Lancet Infect Dis. 2024 Oct 3:S1473-3099(24)00662.
    PubMed    
    
    
    
78. DAS M
    Understanding outbreak preparedness.
    Lancet Infect Dis. 2024;24:1079.
    PubMed    
    
    
    September 2024
79. HAPPLE C, Hoffmann M, Kempf A, Nehlmeier I, et al
    Humoral immunity after mRNA SARS-CoV-2 omicron JN.1 vaccination.
    Lancet Infect Dis. 2024 Sep 25:S1473-3099(24)00603.
    PubMed    
    
    
    
80. WANG WX, Zhu FC
    COVID-19 immunisation strategies for adolescents.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00563.
    PubMed    
    
    
    
81. FIGUEROA AL, Torres D, Reyes-Acuna C, Matherne P, et al
    Safety and immunogenicity of a single-dose omicron-containing COVID-19 vaccination in adolescents: an open-label, single-arm, phase 2/3 trial.
    Lancet Infect Dis. 2024 Sep 24:S1473-3099(24)00501.
    PubMed     Abstract available
    
    
    
82. TERSTAPPEN J, Hak SF, Bhan A, Bogaert D, et al
    The respiratory syncytial virus vaccine and monoclonal antibody landscape: the road to global access.
    Lancet Infect Dis. 2024 Sep 23:S1473-3099(24)00455.
    PubMed     Abstract available
    
    
    
83. LAWSON M
    Globalisation and COVID-19.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00621.
    PubMed    
    
    
    
84. OLBRICH L, Franckling-Smith Z, Larsson L, Sabi I, et al
    Sequential and parallel testing for microbiological confirmation of tuberculosis disease in children in five low-income and middle-income countries: a secondary analysis of the RaPaed-TB study.
    Lancet Infect Dis. 2024 Sep 20:S1473-3099(24)00494.
    PubMed     Abstract available
    
    
    
85. RUSSELL TW, Townsley H, Hellewell J, Gahir J, et al
    Real-time estimation of immunological responses against emerging SARS-CoV-2 variants in the UK: a mathematical modelling study.
    Lancet Infect Dis. 2024 Sep 11:S1473-3099(24)00484.
    PubMed     Abstract available
    
    
    
86. POLETTI P
    Kinetics of neutralising antibodies against SARS-CoV-2 variants.
    Lancet Infect Dis. 2024 Sep 11:S1473-3099(24)00513.
    PubMed    
    
    
    
87. WHELAN MG, Ware H, Ranka H, Kenny S, et al
    ArboTracker: a multipathogen dashboard and data platform for arbovirus seroprevalence studies.
    Lancet Infect Dis. 2024 Sep 10:S1473-3099(24)00585.
    PubMed    
    
    
    
88. HARRIS V, Holmes J, Gbinigie-Thompson O, Rahman NM, et al
    Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
    Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00431.
    PubMed     Abstract available
    
    
    
89. 
    Global, regional, and national burden of upper respiratory infections and otitis media, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
    Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00430.
    PubMed     Abstract available
    
    
    
90. AL-ALY Z
    SARS-CoV-2 antivirals and post-COVID-19 condition.
    Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00436.
    PubMed    
    
    
    
91. ISA F, Gonzalez Ortiz AM, Meyer J, Hamilton JD, et al
    Effect of timing of casirivimab and imdevimab administration relative to mRNA-1273 COVID-19 vaccination on vaccine-induced SARS-CoV-2 neutralising antibody responses: a prospective, open-label, phase 2, randomised controlled trial.
    Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00421.
    PubMed     Abstract available
    
    
    
92. BLOTT J
    Facing COVID-19 in South Africa.
    Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00583.
    PubMed    
    
    
    
93. BAUER DLV
    Weighing up monoclonals and vaccination against COVID-19.
    Lancet Infect Dis. 2024 Sep 2:S1473-3099(24)00559.
    PubMed    
    
    
    
94. BURKI T
    First report from the UK COVID-19 Inquiry.
    Lancet Infect Dis. 2024;24:e555-e556.
    PubMed    
    
    
    
95. JESUDASON T
    Limited progress towards immunisation targets in 2023.
    Lancet Infect Dis. 2024;24:e553.
    PubMed    
    
    
    
96. BAGCCHI S
    Phyllis Dako-Gyeke.
    Lancet Infect Dis. 2024;24:950.
    PubMed    
    
    
    
97. TANUI CK, Ndembi N, Kebede Y, Tessema SK, et al
    Artificial intelligence to transform public health in Africa.
    Lancet Infect Dis. 2024;24:e542.
    PubMed    
    
    
    
98. FALSEY AR, Hosman T, Bastian AR, Vandenberghe S, et al
    Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.
    Lancet Infect Dis. 2024;24:1015-1024.
    PubMed     Abstract available
    
    
    August 2024
99. KAKU Y, Uriu K, Okumura K, Ito J, et al
    Virological characteristics of the SARS-CoV-2 KP.3.1.1 variant.
    Lancet Infect Dis. 2024 Aug 16:S1473-3099(24)00505.
    PubMed    
    
    
    
100. PHAM TM, Zhang Y, Nevers M, Li H, et al
     Trends in infection incidence and antimicrobial resistance in the US Veterans Affairs Healthcare System: a nationwide retrospective cohort study (2007-22).
     Lancet Infect Dis. 2024 Aug 13:S1473-3099(24)00416.
     PubMed     Abstract available
     
     
     
101. KIRBY T
     Outbreaks compound Brazil's flooding disaster.
     Lancet Infect Dis. 2024;24:e490.
     PubMed    
     
     
     
102. KIRBY T
     Naomi Lucchi-from malaria to pandemic preparedness.
     Lancet Infect Dis. 2024;24:812.
     PubMed    
     
     
     
103. THE LANCET INFECTIOUS DISEASES
     Have we learned anything?
     Lancet Infect Dis. 2024;24:793.
     PubMed    
     
     
     
104. TOLEDO ME, Monteagudo Diaz S, Montenegro Calderon T, Kreppel K, et al
     Preparedness for emerging epidemic threats: detection of Oropouche circulation in Cuba.
     Lancet Infect Dis. 2024;24:e484.
     PubMed    
     
     
     
105. SHERWOOD-MARTIN H
     Poor leadership or institutional flaws?
     Lancet Infect Dis. 2024;24:816.
     PubMed    
     
     
     
106. BISBAS G
     Reflecting on the cost of recurrent conflicts for the USA.
     Lancet Infect Dis. 2024;24:813.
     PubMed    
     
     
     
107. KEDDY KH, Gobena T
     The continuing challenge of infectious diseases.
     Lancet Infect Dis. 2024;24:800-801.
     PubMed    
     
     
     July 2024
108. TOLENTINO JE, Lytras S, Ito J, Holmes EC, et al
     Recombination as an evolutionary driver of MERS-related coronavirus emergence.
     Lancet Infect Dis. 2024 Jul 24:S1473-3099(24)00461.
     PubMed    
     
     
     
109. GRAY GE, Mngadi K, Lavreys L, Nijs S, et al
     Mosaic HIV-1 vaccine regimen in southern African women (Imbokodo/HVTN 705/HPX2008): a randomised, double-blind, placebo-controlled, phase 2b trial.
     Lancet Infect Dis. 2024 Jul 19:S1473-3099(24)00358.
     PubMed     Abstract available
     
     
     
110. CHOI MH, Wan EYF, Wong ICK, Chan EWY, et al
     Comparative effectiveness of combination therapy with nirmatrelvir-ritonavir and remdesivir versus monotherapy with remdesivir or nirmatrelvir-ritonavir in patients hospitalised with COVID-19: a target trial emulation study.
     Lancet Infect Dis. 2024 Jul 15:S1473-3099(24)00353.
     PubMed     Abstract available
     
     
     
111. AKINOSOGLOU K, Gogos C
     Antiviral therapy for patients with COVID-19: mix and match.
     Lancet Infect Dis. 2024 Jul 15:S1473-3099(24)00407.
     PubMed    
     
     
     
112. BIJKER EM, Horn L, LaCourse S, MacLean EL, et al
     The inclusion of children and adolescents in tuberculosis diagnostic development and evaluation-a consensus statement.
     Lancet Infect Dis. 2024 Jul 3:S1473-3099(24)00339.
     PubMed     Abstract available
     
     
     
113. DUNSMUIR H
     Managing loss during the COVID-9 pandemic.
     Lancet Infect Dis. 2024;24:683.
     PubMed    
     
     
     
114. BUERANO CC, Morita K
     Single dose of Dengvaxia vaccine: is it a cause for alarm?
     Lancet Infect Dis. 2024;24:670-671.
     PubMed    
     
     
     June 2024
115. KAKU Y, Yo MS, Tolentino JE, Uriu K, et al
     Virological characteristics of the SARS-CoV-2 KP.3, LB.1, and KP.2.3 variants.
     Lancet Infect Dis. 2024 Jun 27:S1473-3099(24)00415.
     PubMed    
     
     
     
116. GEERS D, Gommers L, Tan NH, Bogers S, et al
     Profiling the SARS-CoV-2-specific T-cell response.
     Lancet Infect Dis. 2024 Jun 20:S1473-3099(24)00377.
     PubMed    
     
     
     
117. DE LUSIGNAN S, Shi T, Fowler T, Andrews N, et al
     Sleeper frameworks for Pathogen X: surveillance, risk stratification, and the effectiveness and safety of therapeutic interventions.
     Lancet Infect Dis. 2024 Jun 3:S1473-3099(24)00352.
     PubMed    
     
     
     
118. HALL P
     Highlights of ESCMID Global 2024.
     Lancet Infect Dis. 2024;24:e357.
     PubMed    
     
     
     
119. VENKATESAN P
     Alasdair Macintosh Geddes.
     Lancet Infect Dis. 2024;24:577.
     PubMed    
     
     
     May 2024
120. KAKU Y, Uriu K, Kosugi Y, Okumura K, et al
     Virological characteristics of the SARS-CoV-2 KP.2 variant.
     Lancet Infect Dis. 2024 May 20:S1473-3099(24)00298.
     PubMed    
     
     
     
121. MOUSTSEN-HELMS IR, Bager P, Larsen TG, Moller FT, et al
     Relative vaccine protection, disease severity, and symptoms associated with the SARS-CoV-2 omicron subvariant BA.2.86 and descendant JN.1 in Denmark: a nationwide observational study.
     Lancet Infect Dis. 2024 May 15:S1473-3099(24)00220.
     PubMed     Abstract available
     
     
     
122. INGHAMMAR M, Kahn F
     Immune evasiveness of SARS-CoV-2 variants and vaccine selection.
     Lancet Infect Dis. 2024 May 15:S1473-3099(24)00286.
     PubMed    
     
     
     
123. SORIANO V, Moreno-Torres V
     Oral antivirals for acute symptoms and post-acute sequelae in SARS-CoV-2 infection.
     Lancet Infect Dis. 2024 May 3:S1473-3099(24)00258.
     PubMed    
     
     
     
124. WANG H, Wei Y, Hung CT, Lin G, et al
     Association of nirmatrelvir-ritonavir with post-acute sequelae and mortality in patients admitted to hospital with COVID-19: a retrospective cohort study.
     Lancet Infect Dis. 2024 May 3:S1473-3099(24)00217.
     PubMed     Abstract available
     
     
     
125. VENKATESAN P
     Tobias Welte.
     Lancet Infect Dis. 2024;24:457.
     PubMed    
     
     
     
126. MOODY J
     On the frontline during the COVID-19 pandemic.
     Lancet Infect Dis. 2024;24:464.
     PubMed    
     
     
     
127. KAZI F, Mushtaq A
     Nuria Izquierdo-Useros-fighting the good fight.
     Lancet Infect Dis. 2024;24:458.
     PubMed    
     
     
     
128. DE AMBROGI M
     A summer cold.
     Lancet Infect Dis. 2024;24:461.
     PubMed    
     
     
     
129. LIN DY, Huang S, Milinovich A, Duggal A, et al
     Effectiveness of XBB.1.5 vaccines and antiviral drugs against severe outcomes of omicron infection in the USA.
     Lancet Infect Dis. 2024;24:e278-e280.
     PubMed    
     
     
     
130. KOCHER K, Moosmann C, Drost F, Schulein C, et al
     Adaptive immune responses are larger and functionally preserved in a hypervaccinated individual.
     Lancet Infect Dis. 2024;24:e272-e274.
     PubMed    
     
     
     
131. KEDDY KH, Tadesse BT
     Inaccessible: health, wealth, governance, and equity in low-income and middle-income countries.
     Lancet Infect Dis. 2024;24:444-445.
     PubMed    
     
     
     April 2024
132. ARES-GOMEZ S, Mallah N, Santiago-Perez MI, Pardo-Seco J, et al
     Effectiveness and impact of universal prophylaxis with nirsevimab in infants against hospitalisation for respiratory syncytial virus in Galicia, Spain: initial results of a population-based longitudinal study.
     Lancet Infect Dis. 2024 Apr 30:S1473-3099(24)00215.
     PubMed     Abstract available
     
     
     
133. WONGNAK P, Schilling WHK, Jittamala P, Boyd S, et al
     Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV).
     Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00183.
     PubMed     Abstract available
     
     
     
134. VISSER LG
     Identifying efficacious SARS-CoV-2 antivirals in a changing immune landscape.
     Lancet Infect Dis. 2024 Apr 24:S1473-3099(24)00254.
     PubMed    
     
     
     
135. BUONSENSO D, Tantisira KG
     Long COVID and SARS-CoV-2 persistence: new answers, more questions.
     Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00216.
     PubMed    
     
     
     
136. ZUO W, He D, Liang C, Du S, et al
     The persistence of SARS-CoV-2 in tissues and its association with long COVID symptoms: a cross-sectional cohort study in China.
     Lancet Infect Dis. 2024 Apr 22:S1473-3099(24)00171.
     PubMed     Abstract available
     
     
     
137. JIN SL, Kolis J, Parker J, Proctor DA, et al
     Social histories of public health misinformation and infodemics: case studies of four pandemics.
     Lancet Infect Dis. 2024 Apr 19:S1473-3099(24)00105.
     PubMed     Abstract available
     
     
     
138. 
     Global burden associated with 85 pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019.
     Lancet Infect Dis. 2024 Apr 16:S1473-3099(24)00158.
     PubMed     Abstract available
     
     
     
139. 
     Global, regional, and national incidence and mortality burden of non-COVID-19 lower respiratory infections and aetiologies, 1990-2021: a systematic analysis from the Global Burden of Disease Study 2021.
     Lancet Infect Dis. 2024 Apr 15:S1473-3099(24)00176.
     PubMed     Abstract available
     
     
     
140. PELUSO MJ, Swank ZN, Goldberg SA, Lu S, et al
     Plasma-based antigen persistence in the post-acute phase of COVID-19.
     Lancet Infect Dis. 2024 Apr 8:S1473-3099(24)00211.
     PubMed    
     
     
     
141. DE MENEZES NEVES PDM, Mohrbacher S, Lobato Vasques I, Barreira Cavalcante L, et al
     Renal infarction secondary to Aspergillus spp. embolism following COVID-19.
     Lancet Infect Dis. 2024;24:e266-e267.
     PubMed    
     
     
     March 2024
142. LARIVIERE Y, Matuvanga TZ, Osang'ir BI, Milolo S, et al
     Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccine regimen plus Ad26.ZEBOV booster at 1 year versus 2 years in health-care and front-line workers in the Democratic Republic of the Congo: secondary and exploratory outcomes of an open-label, randomised
     Lancet Infect Dis. 2024 Mar 26:S1473-3099(24)00058.
     PubMed     Abstract available
     
     
     
143. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
     Increased faecal shedding in SARS-CoV-2 variants BA.2.86 and JN.1.
     Lancet Infect Dis. 2024 Mar 21:S1473-3099(24)00155.
     PubMed    
     
     
     
144. DIXIT A, Bennett R, Ali K, Griffin C, et al
     Interim safety and immunogenicity of COVID-19 omicron BA.1 variant-containing vaccine in children in the USA: an open-label non-randomised phase 3 trial.
     Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00101.
     PubMed     Abstract available
     
     
     
145. LI SM, Zhu FC
     The era of SARS-CoV-2 variants calls for an urgent strategy for COVID-19 vaccination in children.
     Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00157.
     PubMed    
     
     
     
146. 
     Global, regional, and national age-specific progress towards the 2020 milestones of the WHO End TB Strategy: a systematic analysis for the Global Burden of Disease Study 2021.
     Lancet Infect Dis. 2024 Mar 19:S1473-3099(24)00007.
     PubMed     Abstract available
     
     
     
147. ZHANG R, Hung IF
     Bivalent (Omicron BA.5/ancestral) recombinant spike protein vaccine: a promising booster.
     Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00156.
     PubMed    
     
     
     
148. BENNETT C, Woo W, Bloch M, Cheung K, et al
     Immunogenicity and safety of a bivalent (omicron BA.5 plus ancestral) SARS-CoV-2 recombinant spike protein vaccine as a heterologous booster dose: interim analysis of a phase 3, non-inferiority, randomised, clinical trial.
     Lancet Infect Dis. 2024 Mar 6:S1473-3099(24)00077.
     PubMed     Abstract available
     
     
     
149. BILSEN MP, Conroy SP, Schneeberger C, Platteel TN, et al
     A reference standard for urinary tract infection research: a multidisciplinary Delphi consensus study.
     Lancet Infect Dis. 2024 Mar 5:S1473-3099(23)00778.
     PubMed     Abstract available
     
     
     
150. KOUTSAKOS M, Rockman S, Krammer F
     Is eradication of influenza B viruses possible?
     Lancet Infect Dis. 2024 Mar 4:S1473-3099(24)00132.
     PubMed    
     
     
     February 2024
151. POUKKA E, Auranen K, Baum U
     Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies.
     Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00106.
     PubMed    
     
     
     
152. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
     Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors' reply.
     Lancet Infect Dis. 2024 Feb 22:S1473-3099(24)00107.
     PubMed    
     
     
     
153. PLEY C, Kampmann B
     Access to respiratory syncytial virus preventive tools for neonates and infants in Europe.
     Lancet Infect Dis. 2024 Feb 19:S1473-3099(24)00084.
     PubMed    
     
     
     
154. FAFI I, Assad Z, Lenglart L, Valtuille Z, et al
     Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices.
     Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00081.
     PubMed    
     
     
     
155. LI Y
     Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices - Author's reply.
     Lancet Infect Dis. 2024 Feb 15:S1473-3099(24)00082.
     PubMed    
     
     
     
156. MACHKOVECH HM, Hahn AM, Garonzik Wang J, Grubaugh ND, et al
     Persistent SARS-CoV-2 infection: significance and implications.
     Lancet Infect Dis. 2024 Feb 7:S1473-3099(23)00815.
     PubMed     Abstract available
     
     
     
157. MARKING U, Bladh O, Aguilera K, Yang Y, et al
     Humoral immune responses to the monovalent XBB.1.5-adapted BNT162b2 mRNA booster in Sweden.
     Lancet Infect Dis. 2024;24:e80-e81.
     PubMed    
     
     
     
158. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
     Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2.
     Lancet Infect Dis. 2024 Feb 1:S1473-3099(24)00060.
     PubMed    
     
     
     
159. BERTRAN M, D'Aeth JC, Abdullahi F, Eletu S, et al
     Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study.
     Lancet Infect Dis. 2024 Feb 1:S1473-3099(23)00706.
     PubMed     Abstract available
     
     
     January 2024
160. DENNING DW
     Global incidence and mortality of severe fungal disease.
     Lancet Infect Dis. 2024 Jan 12:S1473-3099(23)00692.
     PubMed     Abstract available
     
     
     
161. COSSMANN A, Hoffmann M, Stankov MV, Lurken K, et al
     Immune responses following BNT162b2 XBB.1.5 vaccination in patients on haemodialysis in Germany.
     Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00783.
     PubMed    
     
     
     
162. KOSUGI Y, Kaku Y, Hinay AA Jr, Guo Z, et al
     Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals.
     Lancet Infect Dis. 2024 Jan 8:S1473-3099(23)00784.
     PubMed    
     
     
     
163. HANSEN CH, Moustsen-Helms IR, Rasmussen M, Soborg B, et al
     Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study.
     Lancet Infect Dis. 2024 Jan 5:S1473-3099(23)00746.
     PubMed    
     
     
     
164. KAKU Y, Okumura K, Padilla-Blanco M, Kosugi Y, et al
     Virological characteristics of the SARS-CoV-2 JN.1 variant.
     Lancet Infect Dis. 2024 Jan 3:S1473-3099(23)00813.
     PubMed    
     
     
     December 2023
165. CONG B, Koc U, Bandeira T, Bassat Q, et al
     Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis.
     Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00630.
     PubMed     Abstract available
     
     
     
166. ODA Y, Kumagai Y, Kanai M, Iwama Y, et al
     Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial.
     Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00650.
     PubMed     Abstract available
     
     
     
167. HERFST S, de Vries RD
     Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants.
     Lancet Infect Dis. 2023 Dec 20:S1473-3099(23)00734.
     PubMed    
     
     
     
168. MONTGOMERY MP, Morris SE, Rolfes MA, Kittikraisak W, et al
     The role of asymptomatic infections in influenza transmission: what do we really know.
     Lancet Infect Dis. 2023 Dec 18:S1473-3099(23)00619.
     PubMed     Abstract available
     
     
     
169. YANG S, Yu Y, Xu Y, Jian F, et al
     Fast evolution of SARS-CoV-2 BA.2.86 to JN.1 under heavy immune pressure.
     Lancet Infect Dis. 2023 Dec 15:S1473-3099(23)00744.
     PubMed    
     
     
     
170. GANDHI M
     Post-viral sequelae of COVID-19 and influenza.
     Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00762.
     PubMed    
     
     
     
171. XIE Y, Choi T, Al-Aly Z
     Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study.
     Lancet Infect Dis. 2023 Dec 14:S1473-3099(23)00684.
     PubMed     Abstract available
     
     
     
172. RAMAN B, Ramasamy MN
     Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework?
     Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00735.
     PubMed    
     
     
     
173. LAU RI, Su Q, Lau ISF, Ching JYL, et al
     A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial.
     Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00685.
     PubMed     Abstract available
     
     
     
174. ZUO F, Cao Y, Sun R, Yisimayi A, et al
     Neutralisation activity of mucosal IgA against XBB sublineages and BA.2.86.
     Lancet Infect Dis. 2023 Dec 7:S1473-3099(23)00732.
     PubMed    
     
     
     
175. CARR EJ, Dowgier G, Greenwood D, Herman LS, et al
     SARS-CoV-2 mucosal neutralising immunity after vaccination.
     Lancet Infect Dis. 2023 Dec 6:S1473-3099(23)00705.
     PubMed    
     
     
     
176. BURKI T
     UK Covid-19 Inquiry.
     Lancet Infect Dis. 2023;23:e516-e517.
     PubMed    
     
     
     
177. BAGCCHI S
     Boost for COVID-19 testing in the USA.
     Lancet Infect Dis. 2023;23:e514.
     PubMed    
     
     
     November 2023
178. DE LUSIGNAN S, Hobbs FR, Sheikh A
     Lessons from the English primary care sentinel network's response to the COVID-19 pandemic.
     Lancet Infect Dis. 2023 Nov 28:S1473-3099(23)00736.
     PubMed    
     
     
     
179. GOTTLIEB RL, Paredes R
     Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19.
     Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00633.
     PubMed    
     
     
     
180. FAN X, Dai X, Ling Y, Wu L, et al
     Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study.
     Lancet Infect Dis. 2023 Nov 22:S1473-3099(23)00577.
     PubMed     Abstract available
     
     
     
181. STANKOV MV, Hoffmann M, Gutierrez Jauregui R, Cossmann A, et al
     Humoral and cellular immune responses following BNT162b2 XBB.1.5 vaccination.
     Lancet Infect Dis. 2023 Nov 20:S1473-3099(23)00690.
     PubMed    
     
     
     
182. LASSAUNIERE R, Polacek C, Utko M, Sorensen KM, et al
     Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1.
     Lancet Infect Dis. 2023 Nov 7:S1473-3099(23)00682.
     PubMed    
     
     
     
183. JESUDASON T
     New licensing agreements for COVID-19.
     Lancet Infect Dis. 2023;23:e471.
     PubMed    
     
     
     October 2023
184. OLBRICH L, Verghese VP, Franckling-Smith Z, Sabi I, et al
     Diagnostic accuracy of a three-gene Mycobacterium tuberculosis host response cartridge using fingerstick blood for childhood tuberculosis: a multicentre prospective study in low-income and middle-income countries.
     Lancet Infect Dis. 2023 Oct 30:S1473-3099(23)00491.
     PubMed     Abstract available
     
     
     
185. SIMPSON CR, Robertson C, McMenamin J, Ritchie LD, et al
     Developing the EAVE III platform for future health crises.
     Lancet Infect Dis. 2023 Oct 12:S1473-3099(23)00626.
     PubMed    
     
     
     
186. GROBUSCH MP, Ruiz Del Portal Luyten C, Visser BJ, de Jong HK, et al
     Overcoming publication and dissemination bias in infectious diseases clinical trials.
     Lancet Infect Dis. 2023 Oct 11:S1473-3099(23)00455.
     PubMed     Abstract available
     
     
     
187. WANNIGAMA DL, Amarasiri M, Phattharapornjaroen P, Hurst C, et al
     Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand.
     Lancet Infect Dis. 2023 Oct 6:S1473-3099(23)00620.
     PubMed    
     
     
     
188. FAUST JS
     The therapeutic validation of long COVID.
     Lancet Infect Dis. 2023;23:1096-1097.
     PubMed    
     
     
     September 2023
189. BRAMANTE C
     The power and pressure placed on clinicians and guideline panels.
     Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00557.
     PubMed    
     
     
     
190. SCHILLING WHK, Jittamala P, Watson JA, Boyd S, et al
     Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial.
     Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00493.
     PubMed     Abstract available
     
     
     
191. ONYWERA H, Ondoa P, Nfii F, Ogwell A, et al
     Boosting pathogen genomics and bioinformatics workforce in Africa.
     Lancet Infect Dis. 2023 Sep 28:S1473-3099(23)00394.
     PubMed     Abstract available
     
     
     
192. SHEWARD DJ, Yang Y, Westerberg M, Oling S, et al
     Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses.
     Lancet Infect Dis. 2023 Sep 27:S1473-3099(23)00588.
     PubMed    
     
     
     
193. YANG S, Yu Y, Jian F, Song W, et al
     Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86.
     Lancet Infect Dis. 2023 Sep 19:S1473-3099(23)00573.
     PubMed    
     
     
     
194. URIU K, Ito J, Kosugi Y, Tanaka YL, et al
     Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant.
     Lancet Infect Dis. 2023 Sep 18:S1473-3099(23)00575.
     PubMed    
     
     
     
195. BLOM K, Fjallstrom P, Molnar C, Aberg M, et al
     SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters.
     Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00548.
     PubMed    
     
     
     
196. ZHANG L, Kempf A, Nehlmeier I, Cossmann A, et al
     Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3.
     Lancet Infect Dis. 2023 Sep 13:S1473-3099(23)00547.
     PubMed    
     
     
     
197. KAKU Y, Kosugi Y, Uriu K, Ito J, et al
     Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5.
     Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00553.
     PubMed    
     
     
     
198. WANG Q, Guo Y, Zhang RM, Ho J, et al
     Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6.
     Lancet Infect Dis. 2023 Sep 11:S1473-3099(23)00555.
     PubMed    
     
     
     August 2023
199. MARANDA B, Labbe SM, Lurquin M, Brabant P, et al
     Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
     Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00393.
     PubMed     Abstract available
     
     
     
200. WANG Y, Cao B
     The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases.
     Lancet Infect Dis. 2023 Aug 21:S1473-3099(23)00454.
     PubMed    
     
     
     
201. ABO YN, Jamrozik E, McCarthy JS, Roestenberg M, et al
     Strategic and scientific contributions of human challenge trials for vaccine development: facts versus fantasy.
     Lancet Infect Dis. 2023 Aug 10:S1473-3099(23)00294.
     PubMed     Abstract available
     
     
     
202. GRANT R, Benamouzig D, Catton H, Cheng VC, et al
     COVID-19 pandemic: a catalyst for accelerating global action on patient safety.
     Lancet Infect Dis. 2023 Aug 9:S1473-3099(23)00485.
     PubMed    
     
     
     
203. TAN CY, Chiew CJ, Pang D, Lee VJ, et al
     Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study.
     Lancet Infect Dis. 2023 Aug 2:S1473-3099(23)00373.
     PubMed     Abstract available
     
     
     
204. THE LANCET INFECTIOUS DISEASES
     Where are the long COVID trials?
     Lancet Infect Dis. 2023;23:879.
     PubMed    
     
     
     July 2023
205. MADHI SA, Feikin DR
     Are bivalent vaccines better than ancestral-virus monovalent vaccines in protecting against severe omicron COVID-19?
     Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00425.
     PubMed    
     
     
     
206. MATEO-URDIALES A, Sacco C, Fotakis EA, Del Manso M, et al
     Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
     Lancet Infect Dis. 2023 Jul 18:S1473-3099(23)00374.
     PubMed     Abstract available
     
     
     
207. COHN H, Bloom N, Cai GY, Clark JJ, et al
     Mpox vaccine and infection-driven human immune signatures: an immunological analysis of an observational study.
     Lancet Infect Dis. 2023 Jul 17:S1473-3099(23)00352.
     PubMed     Abstract available
     
     
     
208. CERQUEIRA-SILVA T, Boaventura VS, Barral-Netto M
     Effectiveness of monovalent and bivalent COVID-19 vaccines.
     Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00379.
     PubMed    
     
     
     
209. KIRSEBOM FCM, Andrews N, Stowe J, Ramsay M, et al
     Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study.
     Lancet Infect Dis. 2023 Jul 12:S1473-3099(23)00365.
     PubMed     Abstract available
     
     
     
210. SCHAEFER GO, Atuire CA, Kaur S, Parker M, et al
     The importance of getting the ethics right in a pandemic treaty.
     Lancet Infect Dis. 2023 Jul 5:S1473-3099(23)00364.
     PubMed     Abstract available
     
     
     
211. AL-ALY Z
     Prevention of long COVID: progress and challenges.
     Lancet Infect Dis. 2023;23:776-777.
     PubMed    
     
     
     
212. CARR EJ, Wu MY, Gahir J, Harvey R, et al
     Neutralising immunity to omicron sublineages BQ.1.1, XBB, and XBB.1.5 in healthy adults is boosted by bivalent BA.1-containing mRNA vaccination and previous Omicron infection.
     Lancet Infect Dis. 2023;23:781-784.
     PubMed    
     
     
     June 2023
213. NAKAKUBO S, Kishida N, Okuda K, Kamada K, et al
     Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study.
     Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00271.
     PubMed     Abstract available
     
     
     
214. TSUZUKI S
     The future of COVID-19 surveillance in Japan.
     Lancet Infect Dis. 2023 Jun 30:S1473-3099(23)00292.
     PubMed    
     
     
     
215. CRODA J
     Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges.
     Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00363.
     PubMed    
     
     
     
216. LI JX, Hou LH, Gou JB, Yin ZD, et al
     Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial.
     Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00350.
     PubMed     Abstract available
     
     
     
217. SOLERA JT, Ierullo M, Arbol BG, Mavandadnejad F, et al
     Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients.
     Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00357.
     PubMed    
     
     
     
218. YAMIN D, Yechezkel M, Arbel R, Beckenstein T, et al
     Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study.
     Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00207.
     PubMed     Abstract available
     
     
     
219. MADHI SA, Izu A
     Safety of COVID-19 booster dose: is the juice worth the squeeze?
     Lancet Infect Dis. 2023 Jun 20:S1473-3099(23)00296.
     PubMed    
     
     
     
220. LEE IT, Cosgrove CA, Moore P, Bethune C, et al
     Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial.
     Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00295.
     PubMed     Abstract available
     
     
     
221. SHANG L, Cao B
     Adapted vaccine strategy: facing the persistent challenges of COVID-19.
     Lancet Infect Dis. 2023 Jun 19:S1473-3099(23)00370.
     PubMed    
     
     
     
222. LIN DY, Xu Y, Gu Y, Zeng D, et al
     Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study.
     Lancet Infect Dis. 2023 Jun 16:S1473-3099(23)00272.
     PubMed     Abstract available
     
     
     
223. BRAMANTE CT, Buse JB, Liebovitz DM, Nicklas JM, et al
     Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial.
     Lancet Infect Dis. 2023 Jun 8:S1473-3099(23)00299.
     PubMed     Abstract available
     
     
     
224. WALIA K, Mendelson M, Kang G, Venkatasubramanian R, et al
     How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship?
     Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00124.
     PubMed     Abstract available
     
     
     
225. ALAKIJA A
     Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats.
     Lancet Infect Dis. 2023 Jun 5:S1473-3099(23)00279.
     PubMed     Abstract available
     
     
     
226. KANA BD, Arbuthnot P, Botwe BK, Choonara YE, et al
     Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa.
     Lancet Infect Dis. 2023 Jun 5:S1473-3099(22)00878.
     PubMed     Abstract available
     
     
     May 2023
227. ZHANG R, Hung IF
     CS-2034 mRNA vaccine: a new option for COVID-19 infection?
     Lancet Infect Dis. 2023 May 19:S1473-3099(23)00277.
     PubMed    
     
     
     
228. WU JD, Li JX, Liu J, Wang HM, et al
     Safety, immunogenicity, and efficacy of the mRNA vaccine CS-2034 as a heterologous booster versus homologous booster with BBIBP-CorV in adults aged >/=18 years: a randomised, double-blind, phase 2b trial.
     Lancet Infect Dis. 2023 May 19:S1473-3099(23)00199.
     PubMed     Abstract available
     
     
     
229. BHATIA S, Imai N, Watson OJ, Abbood A, et al
     Lessons from COVID-19 for rescalable data collection.
     Lancet Infect Dis. 2023 May 4:S1473-3099(23)00121.
     PubMed     Abstract available
     
     
     
230. LEE NR, King A, Vigil D, Mullaney D, et al
     Infectious diseases in Indigenous populations in North America: learning from the past to create a more equitable future.
     Lancet Infect Dis. 2023 May 3:S1473-3099(23)00190.
     PubMed     Abstract available
     
     
     
231. YAMASOBA D, Uriu K, Plianchaisuk A, Kosugi Y, et al
     Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant.
     Lancet Infect Dis. 2023 May 3:S1473-3099(23)00278.
     PubMed    
     
     
     
232. IZU A, Nunes MC, Solomon F, Baillie V, et al
     All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study.
     Lancet Infect Dis. 2023 May 1:S1473-3099(23)00200.
     PubMed     Abstract available
     
     
     
233. LEVY C, Cohen R
     Infectious diseases in the COVID-19 era: gaps between countries.
     Lancet Infect Dis. 2023 May 1:S1473-3099(23)00198.
     PubMed    
     
     
     April 2023
234. JUAN-GINER A, Namulwana ML, Kimathi D, Grantz KH, et al
     Immunogenicity and safety of fractional doses of 17D-213 yellow fever vaccine in children (YEFE): a randomised, double-blind, non-inferiority substudy of a phase 4 trial.
     Lancet Infect Dis. 2023 Apr 28:S1473-3099(23)00131.
     PubMed     Abstract available
     
     
     
235. MONACH PA, Branch-Elliman W
     More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants.
     Lancet Infect Dis. 2023 Apr 26:S1473-3099(23)00274.
     PubMed    
     
     
     
236. VASIN AV, Stukova MA
     Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2.
     Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00189.
     PubMed    
     
     
     
237. TAN NH, Geers D, Sablerolles RSG, Rietdijk WJR, et al
     Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
     Lancet Infect Dis. 2023 Apr 20:S1473-3099(23)00140.
     PubMed     Abstract available
     
     
     
238. STOLIAROFF-PEPIN A, Harder T
     Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations.
     Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00187.
     PubMed    
     
     
     
239. ARBEL R, Peretz A, Sergienko R, Friger M, et al
     Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study.
     Lancet Infect Dis. 2023 Apr 13:S1473-3099(23)00122.
     PubMed     Abstract available
     
     
     
240. JENKIN D, Wright D, Folegatti PM, Platt A, et al
     Safety and immunogenicity of a ChAdOx1 vaccine against Rift Valley fever in UK adults: an open-label, non-randomised, first-in-human phase 1 clinical trial.
     Lancet Infect Dis. 2023 Apr 12:S1473-3099(23)00068.
     PubMed     Abstract available
     
     
     
241. SOLERA JT, Arbol BG, Ferreira VH, Kurtesi A, et al
     Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab-cilgavimab.
     Lancet Infect Dis. 2023 Apr 5:S1473-3099(23)00208.
     PubMed    
     
     
     
242. IWASAKI A, Putrino D
     Why we need a deeper understanding of the pathophysiology of long COVID.
     Lancet Infect Dis. 2023;23:393-395.
     PubMed    
     
     
     
243. URAKI R, Ito M, Kiso M, Yamayoshi S, et al
     Antiviral and bivalent vaccine efficacy against an omicron XBB.1.5 isolate.
     Lancet Infect Dis. 2023;23:402-403.
     PubMed    
     
     
     March 2023
244. WANG Q, Bowen A, Tam AR, Valdez R, et al
     SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster.
     Lancet Infect Dis. 2023 Mar 29:S1473-3099(23)00181.
     PubMed    
     
     
     
245. EYRE DW, Futschik M, Tunkel S, Wei J, et al
     Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study.
     Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00129.
     PubMed     Abstract available
     
     
     
246. PRESTEDGE J, Williamson DA
     The performance of rapid antigen tests against SARS-CoV-2 variants.
     Lancet Infect Dis. 2023 Mar 28:S1473-3099(23)00186.
     PubMed    
     
     
     
247. WILKINS D, Langedijk AC, Lebbink RJ, Morehouse C, et al
     Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing data.
     Lancet Infect Dis. 2023 Mar 17:S1473-3099(23)00062.
     PubMed     Abstract available
     
     
     
248. LEWNARD JA, McLaughlin JM, Malden D, Hong V, et al
     Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system.
     Lancet Infect Dis. 2023 Mar 15:S1473-3099(23)00118.
     PubMed     Abstract available
     
     
     
249. TAN CY, Chiew CJ, Pang D, Lee VJ, et al
     Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study.
     Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00060.
     PubMed     Abstract available
     
     
     
250. BOYTON RJ, Altmann DM
     Imprinted hybrid immunity against XBB reinfection.
     Lancet Infect Dis. 2023 Mar 13:S1473-3099(23)00138.
     PubMed    
     
     
     
251. CHEMAITELLY H, Ayoub HH, Tang P, Coyle P, et al
     Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study.
     Lancet Infect Dis. 2023 Mar 10:S1473-3099(23)00058.
     PubMed     Abstract available
     
     
     
252. URAKI R, Ito M, Kiso M, Yamayoshi S, et al
     Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1.
     Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00132.
     PubMed    
     
     
     
253. KUIKEN T, Fouchier RAM, Koopmans MPG
     Being ready for the next influenza pandemic?
     Lancet Infect Dis. 2023 Mar 7:S1473-3099(23)00117.
     PubMed    
     
     
     
254. KIRBY T
     Alemka Markotic-from hantavirus to COVID-19.
     Lancet Infect Dis. 2023;23:292.
     PubMed    
     
     
     
255. SOTO-RIFO R
     Durability of AZD1222 and hybrid humoral immunity against omicron BA.1 and BA.4.
     Lancet Infect Dis. 2023;23:262-263.
     PubMed    
     
     
     February 2023
256. HUANG J, Zhao S, Chong KC, Zhou Y, et al
     Infection rate in Guangzhou after easing the zero-COVID policy: seroprevalence results to ORF8 antigen.
     Lancet Infect Dis. 2023 Feb 17:S1473-3099(23)00112.
     PubMed    
     
     
     
257. WONG CKH, Lau KTK, Au ICH, Lau EHY, et al
     Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study.
     Lancet Infect Dis. 2023 Feb 13:S1473-3099(22)00873.
     PubMed     Abstract available
     
     
     
258. PETROSILLO N
     SARS-CoV-2 rebound with and without antivirals.
     Lancet Infect Dis. 2023 Feb 13:S1473-3099(23)00063.
     PubMed    
     
     
     
259. AGGARWAL NR, Molina KC, Beaty LE, Bennett TD, et al
     Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study.
     Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00011.
     PubMed     Abstract available
     
     
     
260. WONG CKH, Lau KTK, Leung GM
     Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants.
     Lancet Infect Dis. 2023 Feb 10:S1473-3099(23)00056.
     PubMed    
     
     
     
261. YUE C, Song W, Wang L, Jian F, et al
     ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5.
     Lancet Infect Dis. 2023 Feb 3:S1473-3099(23)00010.
     PubMed    
     
     
     
262. CHEMAITELLY H, Ayoub HH, Coyle P, Tang P, et al
     BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents.
     Lancet Infect Dis. 2023 Feb 1:S1473-3099(23)00005.
     PubMed    
     
     
     January 2023
263. URIU K, Ito J, Zahradnik J, Fujita S, et al
     Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant.
     Lancet Infect Dis. 2023 Jan 31:S1473-3099(23)00051.
     PubMed    
     
     
     
264. HOEHL S, Ciesek S
     Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits?
     Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00007.
     PubMed    
     
     
     
265. HE G, Jones JA, Sun W
     COVID-19 travel policies for people from China and discrimination.
     Lancet Infect Dis. 2023 Jan 30:S1473-3099(23)00052.
     PubMed    
     
     
     
266. GIACOBBE DR, Bassetti M
     Too many antibiotics for patients with COVID-19 despite low bacterial infections.
     Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00866.
     PubMed    
     
     
     
267. CHEN JZ, Hoang HL, Yaskina M, Kabbani D, et al
     Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial.
     Lancet Infect Dis. 2023 Jan 27:S1473-3099(22)00832.
     PubMed     Abstract available
     
     
     
268. BOAVENTURA VS, Cerqueira-Silva T, Barral-Netto M
     The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era.
     Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00880.
     PubMed    
     
     
     
269. BOBROVITZ N, Ware H, Ma X, Li Z, et al
     Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression.
     Lancet Infect Dis. 2023 Jan 18:S1473-3099(22)00801.
     PubMed     Abstract available
     
     
     
270. FADLYANA E, Setiabudi D, Kartasasmita CB, Putri ND, et al
     Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial
     Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00800.
     PubMed     Abstract available
     
     
     
271. MARKING U, Bladh O, Havervall S, Svensson J, et al
     7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection.
     Lancet Infect Dis. 2023 Jan 11:S1473-3099(22)00834.
     PubMed    
     
     
     
272. NILLES EJ, Paulino CT, de St Aubin M, Duke W, et al
     Tracking immune correlates of protection for emerging SARS-CoV-2 variants.
     Lancet Infect Dis. 2023 Jan 11:S1473-3099(23)00001.
     PubMed    
     
     
     
273. BRADY OJ, Hofmann B, Colon-Gonzalez FJ, Gibb R, et al
     Relaxation of anti-COVID-19 measures reveals new challenges for infectious disease outbreak forecasting.
     Lancet Infect Dis. 2023 Jan 6:S1473-3099(23)00003.
     PubMed    
     
     
     
274. ARORA P, Cossmann A, Schulz SR, Ramos GM, et al
     Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage.
     Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00831.
     PubMed    
     
     
     
275. MALATO J, Ribeiro RM, Fernandes E, Leite PP, et al
     Stability of hybrid versus vaccine immunity against BA.5 infection over 8 months.
     Lancet Infect Dis. 2023 Jan 5:S1473-3099(22)00833.
     PubMed    
     
     
     December 2022
276. NACHEGA JB, Nsanzimana S, Rawat A, Wilson LA, et al
     Advancing detection and response capacities for emerging and re-emerging pathogens in Africa.
     Lancet Infect Dis. 2022 Dec 20:S1473-3099(22)00723.
     PubMed     Abstract available
     
     
     
277. TSALIK EL, Rouphael NG, Sadikot RT, Rodriguez-Barradas MC, et al
     Efficacy and safety of azithromycin versus placebo to treat lower respiratory tract infections associated with low procalcitonin: a randomised, placebo-controlled, double-blind, non-inferiority trial.
     Lancet Infect Dis. 2022 Dec 13:S1473-3099(22)00735.
     PubMed     Abstract available
     
     
     
278. TSANG NNY, So HC, Cowling BJ, Leung GM, et al
     Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study.
     Lancet Infect Dis. 2022 Dec 12:S1473-3099(22)00732.
     PubMed     Abstract available
     
     
     
279. BRYANT OK, Man KKC, Jani YH, Wong ICK, et al
     Antibiotic prescribing in general practice during COVID-19 and beyond.
     Lancet Infect Dis. 2022 Dec 7:S1473-3099(22)00814.
     PubMed    
     
     
     
280. HOFFMANN M, Behrens GMN, Arora P, Kempf A, et al
     Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation.
     Lancet Infect Dis. 2022 Dec 5:S1473-3099(22)00792.
     PubMed    
     
     
     
281. FLORENTINO PTV, Alves FJO, Cerqueira-Silva T, de Araujo Oliveira V, et al
     Effectiveness of BNT162b2 booster after CoronaVac primary regimen in pregnant people during omicron period in Brazil.
     Lancet Infect Dis. 2022;22:1669-1670.
     PubMed    
     
     
     
282. DEN HARTOG G, van Kasteren PB, Schepp RM, Teirlinck AC, et al
     Decline of RSV-specific antibodies during the COVID-19 pandemic.
     Lancet Infect Dis. 2022 Dec 1:S1473-3099(22)00763.
     PubMed    
     
     
     November 2022
283. POWELL AA, Kirsebom F, Stowe J, Ramsay ME, et al
     Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-neg
     Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00729.
     PubMed     Abstract available
     
     
     
284. IRVING SA, Buchan SA
     Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination.
     Lancet Infect Dis. 2022 Nov 24:S1473-3099(22)00759.
     PubMed    
     
     
     
285. ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
     Omicron sublineage BQ.1.1 resistance to monoclonal antibodies.
     Lancet Infect Dis. 2022 Nov 18:S1473-3099(22)00733.
     PubMed    
     
     
     
286. LINDHOLM DA, Kalil AC
     Deja vu all over again? Monkeypox and the urgent need for randomised controlled trials.
     Lancet Infect Dis. 2022 Nov 15. pii: S1473-3099(22)00722.
     PubMed     Abstract available
     
     
     
287. KENNEDY RB
     Monkeypox infection creates immune signatures of disease progression.
     Lancet Infect Dis. 2022 Nov 7. pii: S1473-3099(22)00691.
     PubMed    
     
     
     
288. NICHOLS RM, Deveau C, Upadhyaya H
     Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic.
     Lancet Infect Dis. 2022;22:1531.
     PubMed    
     
     
     October 2022
289. WANG Q, Li Z, Ho J, Guo Y, et al
     Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation.
     Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00694.
     PubMed    
     
     
     
290. ARORA P, Zhang L, Nehlmeier I, Kempf A, et al
     The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages.
     Lancet Infect Dis. 2022 Oct 31. pii: S1473-3099(22)00693.
     PubMed    
     
     
     
291. PRENDECKI M, Willicombe M
     SARS-CoV-2 vaccine strategies in kidney transplant recipients.
     Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00666.
     PubMed    
     
     
     
292. KHO MML, Messchendorp AL, Frolke SC, Imhof C, et al
     Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial.
     Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00650.
     PubMed     Abstract available
     
     
     
293. DORON S, Gandhi M
     New boosters are here! Who should receive them and when?
     Lancet Infect Dis. 2022 Oct 27. pii: S1473-3099(22)00688.
     PubMed    
     
     
     
294. TARTOF SY, Slezak JM, Puzniak L, Hong V, et al
     BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5.
     Lancet Infect Dis. 2022 Oct 25. pii: S1473-3099(22)00692.
     PubMed    
     
     
     
295. MADHI SA, Kwatra G, Richardson SI, Koen AL, et al
     Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial.
     Lancet Infect Dis. 2022 Oct 20. pii: S1473-3099(22)00596.
     PubMed     Abstract available
     
     
     
296. STANDING JF, Agyeman AA
     Learning and confirming in publicly funded antiviral trials.
     Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00665.
     PubMed    
     
     
     
297. KHOO SH, FitzGerald R, Saunders G, Middleton C, et al
     Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial.
     Lancet Infect Dis. 2022 Oct 19. pii: S1473-3099(22)00644.
     PubMed     Abstract available
     
     
     
298. HANSEN CH, Friis NU, Bager P, Stegger M, et al
     Risk of reinfection, vaccine protection, and severity of infection with the BA.5 omicron subvariant: a nation-wide population-based study in Denmark.
     Lancet Infect Dis. 2022 Oct 18. pii: S1473-3099(22)00595.
     PubMed     Abstract available
     
     
     
299. ANGELO KM, Smith T, Camprubi-Ferrer D, Balerdi-Sarasola L, et al
     Epidemiological and clinical characteristics of patients with monkeypox in the GeoSentinel Network: a cross-sectional study.
     Lancet Infect Dis. 2022 Oct 7. pii: S1473-3099(22)00651.
     PubMed     Abstract available
     
     
     
300. LLEWELYN MJ, Budgell EP, Laskawiec-Szkonter M, Cross ELA, et al
     Antibiotic review kit for hospitals (ARK-Hospital): a stepped-wedge cluster-randomised controlled trial.
     Lancet Infect Dis. 2022 Oct 4. pii: S1473-3099(22)00508.
     PubMed     Abstract available
     
     
     
301. RANSCOMBE P
     Dr Hammond's COVID-19 inquiry.
     Lancet Infect Dis. 2022;22:1433.
     PubMed    
     
     
     September 2022
302. CHIEW CJ, Premikha M, Chong CY, Wei WE, et al
     Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study.
     Lancet Infect Dis. 2022 Sep 28. pii: S1473-3099(22)00573.
     PubMed     Abstract available
     
     
     
303. JIAN F, Yu Y, Song W, Yisimayi A, et al
     Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants.
     Lancet Infect Dis. 2022 Sep 27. pii: S1473-3099(22)00642.
     PubMed    
     
     
     
304. MAITEKI-SEBUGUZI C, Gonahasa S, Kamya MR, Katureebe A, et al
     Effect of long-lasting insecticidal nets with and without piperonyl butoxide on malaria indicators in Uganda (LLINEUP): final results of a cluster-randomised trial embedded in a national distribution campaign.
     Lancet Infect Dis. 2022 Sep 26. pii: S1473-3099(22)00469.
     PubMed     Abstract available
     
     
     
305. BANDYOPADHYAY AS, Zipursky S
     A novel tool to eradicate an ancient scourge: the novel oral polio vaccine type 2 story.
     Lancet Infect Dis. 2022 Sep 23. pii: S1473-3099(22)00582.
     PubMed     Abstract available
     
     
     
306. CARAZO S, Skowronski DM, Brisson M, Barkati S, et al
     Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study.
     Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00578.
     PubMed     Abstract available
     
     
     
307. HUI DS
     Hybrid immunity and strategies for COVID-19 vaccination.
     Lancet Infect Dis. 2022 Sep 21. pii: S1473-3099(22)00640.
     PubMed    
     
     
     
308. ARORA P, Nehlmeier I, Kempf A, Cossmann A, et al
     Lung cell entry, cell-cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75.
     Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00591.
     PubMed    
     
     
     
309. POLAND GA, Kennedy RB, Tosh PK
     Prevention of monkeypox with vaccines: a rapid review.
     Lancet Infect Dis. 2022 Sep 15. pii: S1473-3099(22)00574.
     PubMed     Abstract available
     
     
     
310. HARDT K, Vandebosch A, Sadoff J, Le Gars M, et al
     Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial.
     Lancet Infect Dis. 2022 Sep 13. pii: S1473-3099(22)00506.
     PubMed     Abstract available
     
     
     
311. AMIR O, Goldberg Y, Mandel M, Bar-On YM, et al
     Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study.
     Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00527.
     PubMed     Abstract available
     
     
     
312. IRVING SA, Klein NP
     COVID-19 vaccination protects children and adolescents.
     Lancet Infect Dis. 2022 Sep 9. pii: S1473-3099(22)00575.
     PubMed    
     
     
     
313. GRUELL H, Vanshylla K, Tober-Lau P, Hillus D, et al
     Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage.
     Lancet Infect Dis. 2022 Sep 6. pii: S1473-3099(22)00580.
     PubMed    
     
     
     
314. LAZARUS R, Querton B, Corbic Ramljak I, Dewasthaly S, et al
     Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
     Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00502.
     PubMed     Abstract available
     
     
     
315. GEURTSVANKESSEL CH, de Vries RD
     Evaluating novel COVID-19 vaccines in the current chapter of the pandemic.
     Lancet Infect Dis. 2022 Sep 5. pii: S1473-3099(22)00517.
     PubMed    
     
     
     
316. BARDSLEY M, Morbey RA, Hughes HE, Beck CR, et al
     Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study.
     Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00525.
     PubMed     Abstract available
     
     
     
317. BILLARD MN, Bont LJ
     Quantifying the RSV immunity debt following COVID-19: a public health matter.
     Lancet Infect Dis. 2022 Sep 2. pii: S1473-3099(22)00544.
     PubMed    
     
     
     August 2022
318. WELLS CR, Galvani AP
     Tackling the politicisation of COVID-19 data reporting through open access data sharing.
     Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00505.
     PubMed    
     
     
     
319. DONG E, Ratcliff J, Goyea TD, Katz A, et al
     The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned.
     Lancet Infect Dis. 2022 Aug 31. pii: S1473-3099(22)00434.
     PubMed     Abstract available
     
     
     
320. AABY P, Netea MG, Benn CS
     Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections.
     Lancet Infect Dis. 2022 Aug 26. pii: S1473-3099(22)00498.
     PubMed     Abstract available
     
     
     
321. GAVRIILAKI E, Kokoris S
     COVID-19 sequelae: can long-term effects be predicted?
     Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00529.
     PubMed    
     
     
     
322. PERICO N, Cortinovis M, Suter F, Remuzzi G, et al
     Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents.
     Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00433.
     PubMed     Abstract available
     
     
     
323. DEUEL JW, Lauria E, Lovey T, Zweifel S, et al
     Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo).
     Lancet Infect Dis. 2022 Aug 25. pii: S1473-3099(22)00449.
     PubMed     Abstract available
     
     
     
324. ZAREBSKA-MICHALUK D, Flisiak R
     Early oral antiviral use in patients hospitalised with COVID-19.
     Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00522.
     PubMed    
     
     
     
325. WONG CKH, Au ICH, Lau KTK, Lau EHY, et al
     Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study.
     Lancet Infect Dis. 2022 Aug 24. pii: S1473-3099(22)00507.
     PubMed     Abstract available
     
     
     
326. HALFORD F, Nash S, Tessier E, Kall M, et al
     Variation in reported SARS-CoV-2 cases after testing policy changes.
     Lancet Infect Dis. 2022 Aug 23. pii: S1473-3099(22)00572.
     PubMed    
     
     
     
327. FAUST JS, Renton B, Chen AJ, Du C, et al
     Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state.
     Lancet Infect Dis. 2022 Aug 22. pii: S1473-3099(22)00547.
     PubMed    
     
     
     
328. FRANCO-PAREDES C, Rodriguez-Morales AJ, Henao-Martinez AF, Carrasco P, et al
     The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era.
     Lancet Infect Dis. 2022 Aug 16. pii: S1473-3099(22)00548.
     PubMed    
     
     
     
329. ELLINGTON S, Olson CK
     Safety of mRNA COVID-19 vaccines during pregnancy.
     Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00443.
     PubMed    
     
     
     
330. SADARANGANI M, Soe P, Shulha HP, Valiquette L, et al
     Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study.
     Lancet Infect Dis. 2022 Aug 11. pii: S1473-3099(22)00426.
     PubMed     Abstract available
     
     
     
331. MALLORY RM, Formica N, Pfeiffer S, Wilkinson B, et al
     Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial.
     Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00420.
     PubMed     Abstract available
     
     
     
332. RYCKMAN T, Robsky K, Cilloni L, Zawedde-Muyanja S, et al
     Ending tuberculosis in a post-COVID-19 world: a person-centred, equity-oriented approach.
     Lancet Infect Dis. 2022 Aug 10. pii: S1473-3099(22)00500.
     PubMed     Abstract available
     
     
     
333. FLORENTINO PTV, Millington T, Cerqueira-Silva T, Robertson C, et al
     Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study.
     Lancet Infect Dis. 2022 Aug 8. pii: S1473-3099(22)00451.
     PubMed     Abstract available
     
     
     
334. MARTIN GE, Taiaroa G, Taouk ML, Savic I, et al
     Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices.
     Lancet Infect Dis. 2022 Aug 4. pii: S1473-3099(22)00512.
     PubMed    
     
     
     July 2022
335. MCMENAMIN ME, Nealon J, Lin Y, Wong JY, et al
     Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study.
     Lancet Infect Dis. 2022 Jul 15. pii: S1473-3099(22)00345.
     PubMed     Abstract available
     
     
     
336. SUN F, Lin Y, Wang X, Gao Y, et al
     Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection.
     Lancet Infect Dis. 2022 Jul 14. pii: S1473-3099(22)00430.
     PubMed    
     
     
     
337. HERMAN GA, O'Brien MP, Forleo-Neto E, Sarkar N, et al
     Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial.
     Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00416.
     PubMed     Abstract available
     
     
     
338. FOCOSI D, McConnell S, Casadevall A, Cappello E, et al
     Monoclonal antibody therapies against SARS-CoV-2.
     Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00311.
     PubMed     Abstract available
     
     
     
339. GOTTLIEB RL, Razonable RR
     Stewardship of COVID-19 volunteers by nested trial design.
     Lancet Infect Dis. 2022 Jul 5. pii: S1473-3099(22)00429.
     PubMed    
     
     
     
340. BALAKRISHNAN VS
     2 years of the Access to COVID-19 Tools-Accelerator.
     Lancet Infect Dis. 2022;22:948.
     PubMed    
     
     
     
341. SPANER C, Goubran M, Setiadi A, Chen LYC, et al
     COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes.
     Lancet Infect Dis. 2022;22:937-938.
     PubMed    
     
     
     June 2022
342. ARORA P, Kempf A, Nehlmeier I, Schulz SR, et al
     Augmented neutralisation resistance of emerging omicron subvariants BA.2.12.1, BA.4, and BA.5.
     Lancet Infect Dis. 2022 Jun 28. pii: S1473-3099(22)00422.
     PubMed    
     
     
     
343. LEACH AJ, Wilson N, Arrowsmith B, Beissbarth J, et al
     Immunogenicity, otitis media, hearing impairment, and nasopharyngeal carriage 6-months after 13-valent or ten-valent booster pneumococcal conjugate vaccines, stratified by mixed priming schedules: PREVIX_COMBO and PREVIX_BOOST randomised controlled tr
     Lancet Infect Dis. 2022 Jun 27. pii: S1473-3099(22)00272.
     PubMed     Abstract available
     
     
     
344. MARIATULQABTIAH AR, Buttigieg KR
     COVID-19 vaccinations for children.
     Lancet Infect Dis. 2022 Jun 24. pii: S1473-3099(22)00414.
     PubMed    
     
     
     
345. WELLS CR, Galvani AP
     The global impact of disproportionate vaccination coverage on COVID-19 mortality.
     Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00417.
     PubMed    
     
     
     
346. WATSON OJ, Barnsley G, Toor J, Hogan AB, et al
     Global impact of the first year of COVID-19 vaccination: a mathematical modelling study.
     Lancet Infect Dis. 2022 Jun 23. pii: S1473-3099(22)00320.
     PubMed     Abstract available
     
     
     
347. HIGDON MM, Baidya A, Walter KK, Patel MK, et al
     Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant.
     Lancet Infect Dis. 2022 Jun 22. pii: S1473-3099(22)00409.
     PubMed    
     
     
     
348. VADREVU KM, Reddy S, Jogdand H, Ganneru B, et al
     Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study.
     Lancet Infect Dis. 2022 Jun 16. pii: S1473-3099(22)00307.
     PubMed     Abstract available
     
     
     
349. BLOM K, Marking U, Havervall S, Norin NG, et al
     Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection.
     Lancet Infect Dis. 2022 Jun 9. pii: S1473-3099(22)00362.
     PubMed    
     
     
     
350. YAMASOBA D, Kosugi Y, Kimura I, Fujita S, et al
     Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies.
     Lancet Infect Dis. 2022 Jun 8. pii: S1473-3099(22)00365.
     PubMed    
     
     
     
351. USHER AD
     FIND documents dramatic reduction in COVID-19 testing.
     Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00376.
     PubMed    
     
     
     
352. MONGE S, Rojas-Benedicto A, Olmedo C, Mazagatos C, et al
     Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
     Lancet Infect Dis. 2022 Jun 2. pii: S1473-3099(22)00292.
     PubMed     Abstract available
     
     
     
353. ADER F, Bouscambert-Duchamp M, Hites M, Peiffer-Smadja N, et al
     Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19.
     Lancet Infect Dis. 2022;22:764-765.
     PubMed    
     
     
     
354. BRADY OJ, Tian H
     Additional considerations for assessing COVID-19 impact on dengue transmission - Authors' reply.
     Lancet Infect Dis. 2022;22:763.
     PubMed    
     
     
     
355. YEK C, Pacheco AR, Lon C, Leang R, et al
     Additional considerations for assessing COVID-19 impact on dengue transmission.
     Lancet Infect Dis. 2022;22:762-763.
     PubMed    
     
     
     May 2022
356. TRAEGER MW, Guy R, Asselin J, Patel P, et al
     Real-world trends in incidence of bacterial sexually transmissible infections among gay and bisexual men using HIV pre-exposure prophylaxis (PrEP) in Australia following nationwide PrEP implementation: an analysis of sentinel surveillance data.
     Lancet Infect Dis. 2022 May 25. pii: S1473-3099(22)00175.
     PubMed     Abstract available
     
     
     
357. KIRSEBOM FCM, Andrews N, Stowe J, Toffa S, et al
     COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England.
     Lancet Infect Dis. 2022 May 24. pii: S1473-3099(22)00309.
     PubMed    
     
     
     
358. BURN E, Duarte-Salles T, Fernandez-Bertolin S, Reyes C, et al
     Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study.
     Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00223.
     PubMed     Abstract available
     
     
     
359. WHITELEY W, Wood A
     Risk of arterial and venous thromboses after COVID-19.
     Lancet Infect Dis. 2022 May 13. pii: S1473-3099(22)00314.
     PubMed    
     
     
     
360. LOUBET P, Launay O
     What a second booster dose of mRNA COVID-19 vaccines tells us.
     Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00282.
     PubMed    
     
     
     
361. MUNRO APS, Feng S, Janani L, Cornelius V, et al
     Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomis
     Lancet Infect Dis. 2022 May 9. pii: S1473-3099(22)00271.
     PubMed     Abstract available
     
     
     
362. ROMERO-OLMEDO AJ, Schulz AR, Hochstatter S, Gupta DD, et al
     Dynamics of humoral and T-cell immunity after three BNT162b2 vaccinations in adults older than 80 years.
     Lancet Infect Dis. 2022;22:588-589.
     PubMed    
     
     
     
363. SANCHEZ L, Oviedo Rouco S, Pifano M, Ojeda DS, et al
     Antibody durability at 1 year after Sputnik V vaccination.
     Lancet Infect Dis. 2022;22:589-590.
     PubMed    
     
     
     April 2022
364. ODONE A, Vigezzi GP, Baldanti F
     Implications of COVID-19 vaccine effectiveness waning for public health.
     Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00233.
     PubMed    
     
     
     
365. ADLHOCH C, Gomes HC
     Sustainability of surveillance systems for SARS-CoV-2.
     Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00174.
     PubMed    
     
     
     
366. SHEIKH A, Kerr S, Woolhouse M, McMenamin J, et al
     Severity of omicron variant of concern and effectiveness of vaccine boosters against symptomatic disease in Scotland (EAVE II): a national cohort study with nested test-negative design.
     Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00141.
     PubMed     Abstract available
     
     
     
367. BAGER P, Wohlfahrt J, Bhatt S, Stegger M, et al
     Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study.
     Lancet Infect Dis. 2022 Apr 22. pii: S1473-3099(22)00154.
     PubMed     Abstract available
     
     
     
368. SMOLENOV I, Han HH, Li P, Baccarini C, et al
     Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial.
     Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00144.
     PubMed     Abstract available
     
     
     
369. LI JX, Zhu FC
     The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2.
     Lancet Infect Dis. 2022 Apr 18. pii: S1473-3099(22)00162.
     PubMed    
     
     
     
370. LORTHE E, Bellon M, Berthelot J, Michielin G, et al
     A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland.
     Lancet Infect Dis. 2022 Apr 14. pii: S1473-3099(22)00267.
     PubMed    
     
     
     
371. CRAWSHAW AF, Farah Y, Deal A, Rustage K, et al
     Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review.
     Lancet Infect Dis. 2022 Apr 13. pii: S1473-3099(22)00066.
     PubMed     Abstract available
     
     
     
372. ARORA P, Zhang L, Rocha C, Sidarovich A, et al
     Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3.
     Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(22)00224.
     PubMed    
     
     
     
373. WANG B, Giles L, Andraweera P, McMillan M, et al
     Effectiveness and impact of the 4CMenB vaccine against invasive serogroup B meningococcal disease and gonorrhoea in an infant, child, and adolescent programme: an observational cohort and case-control study.
     Lancet Infect Dis. 2022 Apr 12. pii: S1473-3099(21)00754.
     PubMed     Abstract available
     
     
     
374. MENNI C, May A, Polidori L, Louca P, et al
     COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study.
     Lancet Infect Dis. 2022 Apr 8. pii: S1473-3099(22)00146.
     PubMed     Abstract available
     
     
     
375. MUTHU V, Agarwal R, Patel A, Kathirvel S, et al
     Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India.
     Lancet Infect Dis. 2022 Apr 4. pii: S1473-3099(22)00124.
     PubMed     Abstract available
     
     
     
376. KIRBY T
     Kanta Subbarao-confronting influenza and COVID-19.
     Lancet Infect Dis. 2022;22:460.
     PubMed    
     
     
     
377. BURKI T
     Hong Kong's fifth COVID-19 wave-the worst yet.
     Lancet Infect Dis. 2022;22:455-456.
     PubMed    
     
     
     
378. THIRUVENGADAM R, Awasthi A, Bhatnagar S, Garg PK, et al
     Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply.
     Lancet Infect Dis. 2022;22:447.
     PubMed    
     
     
     
379. CHAKRABARTI S, Chakrabarti SS, Chandan G, Kaur U, et al
     Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India.
     Lancet Infect Dis. 2022;22:446-447.
     PubMed    
     
     
     
380. DYSON L
     Modelling results on the impact of COVID-19 testing in schools.
     Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00163.
     PubMed    
     
     
     
381. COLOSI E, Bassignana G, Contreras DA, Poirier C, et al
     Screening and vaccination against COVID-19 to minimise school closure: a modelling study.
     Lancet Infect Dis. 2022 Apr 1. pii: S1473-3099(22)00138.
     PubMed     Abstract available
     
     
     March 2022
382. NORDSTROM P, Ballin M, Nordstrom A
     Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden.
     Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00143.
     PubMed     Abstract available
     
     
     
383. GARG PK, Thiruvengadam R
     Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world.
     Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00207.
     PubMed    
     
     
     
384. TAN HX, Juno JA
     Interplay of infection and vaccination in long-term protection from COVID-19.
     Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00210.
     PubMed    
     
     
     
385. CERQUEIRA-SILVA T, Andrews JR, Boaventura VS, Ranzani OT, et al
     Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study.
     Lancet Infect Dis. 2022 Mar 31. pii: S1473-3099(22)00140.
     PubMed     Abstract available
     
     
     
386. DAL-RE R, Becker SL, Bottieau E, Holm S, et al
     Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach.
     Lancet Infect Dis. 2022 Mar 29. pii: S1473-3099(22)00119.
     PubMed     Abstract available
     
     
     
387. POWELL AA, Kirsebom F, Stowe J, McOwat K, et al
     Effectiveness of BNT162b2 against COVID-19 in adolescents.
     Lancet Infect Dis. 2022 Mar 21. pii: S1473-3099(22)00177.
     PubMed    
     
     
     
388. SHEWARD DJ, Kim C, Ehling RA, Pankow A, et al
     Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study.
     Lancet Infect Dis. 2022 Mar 17. pii: S1473-3099(22)00129.
     PubMed     Abstract available
     
     
     
389. PARKER A, Dawood H
     SARS-CoV-2 transmission: time to rethink public health strategy.
     Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00137.
     PubMed    
     
     
     
390. COHEN C, Kleynhans J, von Gottberg A, McMorrow ML, et al
     SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21.
     Lancet Infect Dis. 2022 Mar 14. pii: S1473-3099(22)00069.
     PubMed     Abstract available
     
     
     
391. WELKER J, Pulido JD, Catanzaro AT, Malvestutto CD, et al
     Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study.
     Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00058.
     PubMed     Abstract available
     
     
     
392. ECKHARDT CM, O'Donnell MR
     CD24Fc: an emerging COVID-19 therapy.
     Lancet Infect Dis. 2022 Mar 11. pii: S1473-3099(22)00125.
     PubMed    
     
     
     
393. PARKER EPK, Desai S, Marti M, O'Brien KL, et al
     Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix?
     Lancet Infect Dis. 2022 Mar 9. pii: S1473-3099(22)00178.
     PubMed    
     
     
     
394. KRANTZ MS, Phillips EJ
     COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA.
     Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00123.
     PubMed    
     
     
     
395. ROSENBLUM HG, Gee J, Liu R, Marquez PL, et al
     Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe.
     Lancet Infect Dis. 2022 Mar 7. pii: S1473-3099(22)00054.
     PubMed     Abstract available
     
     
     
396. DEAN AS, Tosas Auguet O, Glaziou P, Zignol M, et al
     25 years of surveillance of drug-resistant tuberculosis: achievements, challenges, and way forward.
     Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(21)00808.
     PubMed     Abstract available
     
     
     
397. NTOUMI F, Nachega JB, Aklillu E, Chakaya J, et al
     World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis.
     Lancet Infect Dis. 2022 Mar 3. pii: S1473-3099(22)00142.
     PubMed    
     
     
     
398. SASMONO RT, Santoso MS
     Movement dynamics: reduced dengue cases during the COVID-19 pandemic.
     Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00062.
     PubMed    
     
     
     
399. CHEN Y, Li N, Lourenco J, Wang L, et al
     Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study.
     Lancet Infect Dis. 2022 Mar 2. pii: S1473-3099(22)00025.
     PubMed     Abstract available
     
     
     
400. KIRBY T
     Wolfgang Preiser-co-discoverer of SARS-CoV-2 variants.
     Lancet Infect Dis. 2022;22:326.
     PubMed    
     
     
     
401. BURKI T
     Education services in crisis due to COVID-19.
     Lancet Infect Dis. 2022;22:321-322.
     PubMed    
     
     
     
402. SZEPESSY E, Arlett P, Sweeney F, Broich K, et al
     COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
     Lancet Infect Dis. 2022;22:315-316.
     PubMed    
     
     
     
403. DEPOORTERE E, Sowinski S, van Hengel A, Kerstiens B, et al
     COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe.
     Lancet Infect Dis. 2022;22:315.
     PubMed    
     
     
     
404. GUPTA S, Saarikko M, Pfutzner A, Raisanen IT, et al
     Compromised periodontal status could increase mortality for patients with COVID-19.
     Lancet Infect Dis. 2022;22:314.
     PubMed    
     
     
     
405. VILLAR JC, Gumisiriza N, Abreu LG, Maude RJ, et al
     Defining post-COVID condition.
     Lancet Infect Dis. 2022;22:316-317.
     PubMed    
     
     
     
406. SCHLAGENHAUF P, Deuel J
     Concerts and COVID: can the beat go on?
     Lancet Infect Dis. 2022;22:299-301.
     PubMed    
     
     
     February 2022
407. COBELENS F, Suri RK, Helinski M, Makanga M, et al
     Accelerating research and development of new vaccines against tuberculosis: a global roadmap.
     Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(21)00810.
     PubMed     Abstract available
     
     
     
408. VANSHYLLA K, Tober-Lau P, Gruell H, Munn F, et al
     Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults.
     Lancet Infect Dis. 2022 Feb 28. pii: S1473-3099(22)00135.
     PubMed    
     
     
     
409. ABEYWICKREMA M, Goodman AL
     COVID-19 vaccine results might inform malaria vaccine strategies.
     Lancet Infect Dis. 2022 Feb 24. pii: S1473-3099(22)00139.
     PubMed    
     
     

Thank you for your interest in scientific medicine.

AMEDEO COVID-19 is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum